A recombinant antithrombotic and cytoprotective enzyme that acts without increasing the risk of bleeding. AB002 is in Phase One clinical trials for stand-alone emergency use during acute cardiovascular and cerebral ischemia.
A recombinant protein that selectively inhibits the intrinsic blood coagulation cascade upstream of coagulation factor IX (F9). AB012 is in pre-clinical development for use as an antithrombotic agent when the bleeding risk is moderate.
A recombinant protein (monoclonal antibody) that selectively inhibits the intrinsic blood coagulation cascade upstream of coagulation factor XI (F11). AB022 is in pre-clinical development for emergency antithrombotic use in conditions that are intrinsically accompanied with thrombosis and bleeding, such as major surgeries, fractures, crushing and head injuries. AB022 may also improve the outcome of rapidly progressing blood vessel occlusions, such as those that occur during transient ischemic attack (TIA) and stroke. This antibody selectively reduces the procoagulant activity of the contact coagulation factor XII (F12) and may attenuate consumptive coagulopathy (DIC) that is often associated with life-threatening severe infections. Such infections include certain forms of sepsis (peritonitis, listeriosis, anthrax, meningitis, plague, etc.) or RNA viral hemorrhagic fevers (dengue, Ebola, Marburg, Lassa, etc.)